Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is the expectation then that the Oxy market $ drops as well when generics start getting approved?
This is true - makes it a little more difficult to oversee both if they are far apart but I agree with the logic.
Meaning we could see an approval as early as Q1?
It was but then I believe the FDA came out with the additional requirement of the insufflation study and we put it on pause until the funding made sense to complete that last piece.
Man that’s a good lookin list being checked off!
I guess there are worse problems to have. Lol.
Obviously it’s all speculation but talking about being bought out too early vs at the “right” time - what amount per share would you consider too early and what do you think they are capable of getting if they let R&D and growth play out to an ideal level?
Yep the “worst case” scenarios here regarding Vyvanse still have us sitting pretty.
This is excluding Oxy and if Concerta is indeed the 3rd needle mover product.
Add the 2 smaller drugs we should get approval for within the next 4 months or so.
Vigabatrin with Pyros.
Prasco/Burel on Jan 1.
Dexcel wildcard.
Whatever else we don’t know about yet in earlier pipeline stages.
IF we get the same Vyvanse market share Nasrat reported on in an earlier CC for Adderrall, AND IF the market gets cut more than half to 2B, that’s still roughly $136,000,000 in revenues off that one drug.
And from what I can tell, we will be a lot closer time-wise to the first generic Vyvanse entrants (call it 1 to 1.5 years after first generic entry) vs Adderrall XR generics first starting to become available in 2012?
https://gabionline.net/generics/news/Generic-Adderall-XR-approved-in-the-US
If they just failed absolutely. I’m talking like 1 percent of all 3 big drugs coming up, AND assuming the 5.1B drug market drops to 2B… they will STILL more than double revenues to $80M or more.
That’s if they do a totally horrific job at grabbing market share in all 3 new drugs coming up - all 3 of which are “high profile” drugs, some of which are in shortage.
No wonder shorties are panicking.
I hear you. You would think that principle would apply to most if not all legitimate businesses.
Then again, enter Kirko’s one month of Isradipine sales outpacing a year’s worth of sales under a different licensee.
So hyping props it up but bashing doesn’t hold it down?
We’re talking apples and oranges tho. It was Lannett that started selling both Adderralls initially, not Elite. Nasrat has said many times that:
You have way more motivation to sell your own product vs someone else letting it sit in a compendium.
And
Now that we control the pricing, we can be more competitive.
They got between 6 and 7% market share, at least for the month Nasrat referenced, on Adderrall IR after only a couple months on their own. That’s a big boy drug.
Why would we think they can’t do the same for bigger drugs?
True, not by then. But I do think we easily have the potential to get there based on what we know of the biggest upcoming products in the pipeline.
Don’t think Epic Pharma had anything but generics either. The acquirer, as I understand it, wanted a generic entry into the US market.
Same, just so monotonous and unoriginal. Needs some new material, IMO.
That’s easy - because we’re now clearly on an upward trajectory and we know even getting slivers of market share on the biggest upcoming 3 products (that we’re aware of) means doubling, tripling or more from current revenues.
You know all this already but what the hell, I’ll post it again.
https://www.prnewswire.com/news-releases/humanwell-healthcare-group-and-puracap-pharmaceutical-llc-to-acquire-epic-pharma-llc-300243955.html
We will surpass what Epic was performing at when they were acquired.
But it doesn’t matter, right? You’re out at .15, remember?
“Some men just want to watch the world burn.”
That’s fine, stick around.
You’ll get real quiet when some of the big PRs start dropping, bet.
The 3PL company that we’re working with to distribute our drugs to those purchasing them? Seems like it might be based on some info from that site
Examples just looking around at other pharmas like Hikma and whoever Roxane is - other pharmas that received FDA approval letters dealing with first-to-file situations:
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/202090Orig1s000ltredt.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208339Orig1s000ltr.pdf
Looks like if patents are involved, the FDA mentions them and discusses how the company corresponded, such as if the applicant says they were invalidated or whatnot.
Case in point: I don’t think we’ll know if we are first-to-file on the Oxy ANDA until our approval letter or if we hear of another pharma getting it before then.
Lol now we both know that’s some fake news
Welcome. Plenty of goobers around here but we do what we can.
“Looks like Prasco has done nothing for Elite.”
Well the deal doesn’t kick in until 1/1/24, so… lol.
You’ll 100% be here after .15. Lol
Nah no chance he leaves. He’ll be here even after .15, guarantee it.
Sounds like you better sell then if you’re not confident in the company’s future.
Because institutional funds largely can’t own ELTP shares while it is a penny stock.
Because a chunk of brokerages won’t let you trade ELTP at all.
Because the company pivoted from its original abuse deterrent goal and probably scared off some would-be investors from a few rounds of overpromising and under delivering.
Because Elite had to dilute its shares to stay in business and continue funding new drugs, which drags on price.
Because stocks of all calibers go through periods of simply being undervalued or overvalued irrespective of fundamentals.
Because certain individuals admit to having engaged in shorting campaigns on Elite, which drags on price.
Because we’re on the OTC and during periods of extremely low volume, market makers will play games, which drags on price.
We have multiple drugs in the pipeline, plus already approved, that equal several billion dollars in market size. Nasrat is not going to sell the company for not even a double in share price from here when they’ve had independent valuations for over $1 years ago. Seriously, give it a rest.
Doesn’t matter what your personal price target is - it isn’t going to happen.
Everyone here knows, including you, that he isn’t going to sell for 15 cents. Give it a rest.
Like Nasrat said on the last call, they show their contracts and agreements to the DEA to justify the quota they get and the amount they ask for.
You’re also assuming the DEA wouldn’t raise the total “bucket” amount of quota for the industry to address the shortages.
IMO, not a game changer but certainly another positive coming soon and should be the next approval we see, likely in October.
I expect Kirko will also make it another worthwhile generic pursuit. Another arrow in Elite’s quiver!
So to be clear - you “own” 20,000 shares but you want the stock to delist and go to .0001?
Lol who are these amateur clowns
Dude got hooked up. Lol.
Now he better get to work on fixing the stupid March-March fiscal year!
I wondered. Lol. No worries.
I myself am neither. If you are referring to someone else, then yes I think one or both of those may apply to many IDs on this board.
Several things
You can probably guess why. Boiler
Traitor is a bit harsh. If he got an offer for double his salary elsewhere, I won’t fault the guy for taking it.
IMO, better to bring someone back who knows the company very well and will hit the ground running than some of the other clowns that have recently filled the position.
The ELTP Eeyore